Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241839 · ClinicalTrials.gov registry record · Phase 3
Uric Acid and Hypertension in African Americans
A Phase 3 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT00241839 is a Phase 3 study that has completed, run by University of Florida. The registered enrollment target is 150 participants.
The verdict
NCT00241839, a Phase 3 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
This study will test the hypothesis that the administration of a xanthine oxidase inhibitor (allopurinol) will prevent thiazide-induced hyperuricemia, which will result in better blood pressure (BP) control in African Americans.
Interventions
- DRUG Placebo
- DRUG Chlorthalidone
- DRUG Allopurinol
- DRUG Potassium chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-08 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241839
The ClinicalTrials.gov registry entry for NCT00241839 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00241839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00241839 about?
NCT00241839 is a clinical study titled "Uric Acid and Hypertension in African Americans". This study will test the hypothesis that the administration of a xanthine oxidase inhibitor (allopurinol) will prevent thiazide-induced hyperuricemia, which will result in better blood pressure (BP) control in African Americans.
What is the current status of trial NCT00241839?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2005-08. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00241839?
The interventions under investigation include: Placebo (DRUG), Chlorthalidone (DRUG), Allopurinol (DRUG), Potassium chloride (DRUG).
Who is sponsoring clinical trial NCT00241839?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.